David S. Perlin mostly deals with Microbiology, Caspofungin, Echinocandin, Candida albicans and Drug resistance. His Microbiology study frequently links to other fields, such as Mutant. David S. Perlin has included themes like Etest, Mycosis, Micafungin and Susceptibility testing in his Caspofungin study.
In his study, Wild type, Candida parapsilosis and Enzyme is inextricably linked to Fungal protein, which falls within the broad field of Echinocandin. His Candida albicans research integrates issues from Molecular biology, Genotyping and Drug. His work carried out in the field of Drug resistance brings together such families of science as Fungal genetics, Antifungal drug, Gene and Candida auris.
David S. Perlin mainly investigates Microbiology, Echinocandin, Caspofungin, Candida albicans and Candida glabrata. His work in Drug resistance, Aspergillus fumigatus, Micafungin, Anidulafungin and Echinocandins are all subfields of Microbiology research. In his work, Aspergillosis is strongly intertwined with Aspergillus, which is a subfield of Aspergillus fumigatus.
His Echinocandin research is multidisciplinary, relying on both Candida parapsilosis, Drug, Azole, Fungal protein and In vivo. His research integrates issues of Fluconazole and Mutant in his study of Candida albicans. The concepts of his Candida glabrata study are interwoven with issues in Multiple drug resistance and Genotype.
His primary areas of investigation include Microbiology, Echinocandin, Candida glabrata, Internal medicine and Fluconazole. Microbiology is represented through his Candida parapsilosis, Typing, Azole, Candida auris and Amphotericin B research. His Echinocandin study incorporates themes from Aspergillus, Caspofungin, Echinocandins, Enzyme and Drug resistance.
His research in Caspofungin focuses on subjects like Micafungin, which are connected to Pharmacology and Drug. His studies in Drug resistance integrate themes in fields like Mutant and Intensive care medicine. His Fluconazole research incorporates themes from Candida albicans and Corpus albicans.
David S. Perlin spends much of his time researching Microbiology, Echinocandin, Candida glabrata, Drug resistance and ARDS. His Microbiology research is multidisciplinary, incorporating elements of Microsatellite and Avibactam. His Echinocandin research incorporates elements of Minimum inhibitory concentration and CRISPR.
David S. Perlin has researched Candida glabrata in several fields, including Aspergillus fumigatus and Internal medicine, Incidence. His Drug resistance study combines topics from a wide range of disciplines, such as Candida auris, Aspergillus and Intensive care medicine. His work deals with themes such as Sphingolipid, Caspofungin, Echinocandins, Candida tropicalis and Enzyme, which intersect with Aspergillus.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations
Barbara D. Alexander;Melissa D. Johnson;Christopher D. Pfeiffer;Cristina Jiménez-Ortigosa.
Clinical Infectious Diseases (2013)
Frequency and Evolution of Azole Resistance in Aspergillus fumigatus Associated with Treatment Failure
Susan J. Howard;Dasa Cerar;Michael J. Anderson;Ahmed Albarrag.
Emerging Infectious Diseases (2009)
Resistance to echinocandin-class antifungal drugs
David S. Perlin.
Drug Resistance Updates (2007)
Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates
S. Park;R. Kelly;J. Nielsen Kahn;J. Robles.
Antimicrobial Agents and Chemotherapy (2005)
The global problem of antifungal resistance: prevalence, mechanisms, and management
David S Perlin;Riina Rautemaa-Richardson;Ana Alastruey-Izquierdo.
Lancet Infectious Diseases (2017)
A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis Accounts for Reduced Echinocandin Susceptibility
Guillermo Garcia-Effron;Santosh K. Katiyar;Steven Park;Thomas D. Edlind.
Antimicrobial Agents and Chemotherapy (2008)
Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria
M.A. Pfaller;D.J. Diekema;D. Andes;M.C. Arendrup.
Drug Resistance Updates (2011)
High-frequency Triazole Resistance Found In Nonculturable Aspergillus fumigatus from Lungs of Patients with Chronic Fungal Disease
David W. Denning;Steven Park;Cornelia Lass-Florl;Marcin G. Fraczek;Marcin G. Fraczek.
Clinical Infectious Diseases (2011)
Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β-d-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint
Guillermo Garcia-Effron;Samuel Lee;Steven Park;John D. Cleary.
Antimicrobial Agents and Chemotherapy (2009)
Mechanisms of Antifungal Drug Resistance
Leah E. Cowen;Dominique Sanglard;Susan J. Howard;P. David Rogers.
Cold Spring Harbor Perspectives in Medicine (2015)
Journal of Fungi
(Impact Factor: 5.724)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: